On Invalid Date, Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 2023 earnings per share (EPS) of $1.50, up 138.96% year over year. Total Jazz Pharmaceuticals earnings for the quarter were $94.15 million. In the same quarter last year, Jazz Pharmaceuticals's earnings per share (EPS) was -$3.85.
As of Q2 2024, Jazz Pharmaceuticals's earnings has grown year over year. Jazz Pharmaceuticals's earnings in the past year totalled $414.83 million.
What is JAZZ's earnings date?
Jazz Pharmaceuticals's earnings date is Invalid Date. Add JAZZ to your watchlist to be reminded of JAZZ's next earnings announcement.
What was JAZZ's revenue last quarter?
On Invalid Date, Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 2023 revenue of $1.01 billion up 4.1% year over year. In the same quarter last year, Jazz Pharmaceuticals's revenue was $972.12 million.
What was JAZZ's revenue growth in the past year?
As of Q2 2024, Jazz Pharmaceuticals's revenue has grown 4.78% year over year. This is 139.85 percentage points lower than the US Biotechnology industry revenue growth rate of 144.63%. Jazz Pharmaceuticals's revenue in the past year totalled $3.83 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.